Roswell Park Cancer Institute (RPCI) has enhanced Institute science and education activities over the current period of NCI funding. Critical to this progress has been the availability of the CCSG Developmental Funds which serve to nucleate investment of philanthropic and Institute resources for expansion of science and education. The success of these investments is greatly enhanced by effective RPCI Planning and Evaluation processes that identify and evaluate areas of strategic opportunity and need. These processes engage advisory committees (e.g. CCSG External Advisory Board, program-specific External Advisory Boards, Executive Council, CCSG Steering Committee, Shared Resource Directors Committee, Shared Resource Advisory Committees and Institute Strategic Leadership Retreats). High priority needs are identified, and met through the use of Institute funds and philanthropic resources, with a small but very important component (3%) constituted by CCSG Developmental Funds. Developmental Funds are used to recruit outstanding basic, clinical and population scientists, to enhance shared resource infrastructure and to promote programmatic research in strategic high priority areas. During the award period, these funds were used to recruit 17 new CCSG members, 13 of whom have obtained extramural peer-reviewed project or career-development funding with a return on investment (grant funding) of 24:1. Nine (9) shared resources received developmental funding, and this resulted in more use by investigators, enhanced recruitment efforts and additional peer-reviewed funding opportunities. Sixteen (16) research projects were awarded that to date have generated 6 grants or funded supplements (with a well-scored P50 awaiting funding), 8 publications, 9 abstracts, and 5 clinical trials with a return on investment (grant funding) of 11:1. Institute and CCSG Developmental Funds are complemented by philanthropic funding through the Roswell Park Alliance Foundation (RPAF) to reach key Institute strategic goals. In the next award period, RPCI proposes to utilize CCSG Developmental Funds for continued support of faculty recruitment, shared resources and developmental research. These will be strategically selected in accordance with the RPCI strategic plan and ongoing review by evaluation processes. Dr. Donald Trump, Institute Director, has responsibility for final assignment of CCSG and Institute funds.
To drive growth and innovation, Roswell Park Cancer Institute strategically uses developmental funding to support strategic faculty recruitment, novel pilot projects, and shared resource development. These areas are closely tied to going strategic planning and evaluation efforts.
|Wintrob, Zachary A P; Hammel, Jeffrey P; Nimako, George K et al. (2017) Insulin use, hormone receptor status and hematopoietic cytokines? circulation in women with diabetes mellitus and breast cancer. Data Brief 11:382-390|
|Murphy, Maureen E; Liu, Song; Yao, Song et al. (2017) A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer 3:5|
|Liu, Song; Kumari, Sangeeta; Hu, Qiang et al. (2017) A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife 6:|
|Espinal, Allyson C; Buas, Matthew F; Wang, Dan et al. (2017) FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women? Breast Cancer Res Treat 166:559-568|
|Danaher, Patrick; Warren, Sarah; Dennis, Lucas et al. (2017) Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer 5:18|
|Oakley, Emily; Bellnier, David A; Hutson, Alan et al. (2017) Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer. Lasers Surg Med 49:599-608|
|Gage-Bouchard, Elizabeth A (2017) Social support, flexible resources, and health care navigation. Soc Sci Med 190:111-118|
|Moore, Kathleen N; Tritchler, David; Kaufman, Kenneth M et al. (2017) Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:396-401|
|Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425|
|Ho, Christine M; McCarthy, Philip L; Wallace, Paul K et al. (2017) Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Adv 1:1056-1066|
Showing the most recent 10 out of 1391 publications